Table 6.
The effect of CKD on hypertrophy-associated selected targets of miR-212.
| Gene name | Gene symbol | log2 change | SD log2 change | p-value | Fold change |
|---|---|---|---|---|---|
| Mitogen activated protein kinase 1 (ERK2) | Mapk1 | −0.22 | 0.24 | 0.000 | −1.17 |
| Myocyte enhancer factor 2a | Mef2a | −0.11 | 0.29 | 0.026 | −1.08 |
| Protein kinase AMP-activated catalytic subunit alpha 2 (AMPK) | Prkaa2 | −0.22 | 0.34 | 0.000 | −1.16 |
| DnaJ heat shock protein family (HSP40) member A2 | Dnaja2 | −0.18 | 0.18 | 0.002 | 0.88 |
| Sirtuin 1, transcript variant X1 (predicted) | Sirt1 | −0.02 | 0.34 | 0.750 | −1.01 |
| Phosphatase and tensin homolog | Pten | 0.13 | 0.25 | 0.003 | 1.10 |
Gene expression ratios (CKD vs. control). Fold change of <−1.75 or >1.75 (repression or overexpression, respectively) and a p-value of <0.05 were considered as a significant change*, n = 5–6, unpaired t-test or Mann Whitney U test (Dnaja2).